163465-86-9

Usage

Uses

Used in Pharmaceutical Industry:
1(2H)-Naphthalenone, 7-[(3-chlorophenyl)methoxy]-3,4-dihydrois used as an intermediate in the synthesis of pharmaceuticals for its potential role in the development of new drugs. The presence of the 3-chlorophenylmethyl group in its structure may contribute to the compound's effectiveness in targeting specific biological pathways, making it a promising candidate for drug design.
Used in Agrochemical Industry:
In the agrochemical industry, 1(2H)-Naphthalenone, 7-[(3-chlorophenyl)methoxy]-3,4-dihydrois utilized as a building block in the creation of new pesticides. Its unique chemical structure may provide specific properties that enhance the effectiveness of these pesticides, offering potential benefits in crop protection and management.
Used in Scientific Research:
This chemical compound is also used in scientific research as a valuable tool for studying various biological and chemical processes. The 3-chlorophenylmethyl group may impart specific interactions with biological targets, making it an interesting subject for researchers exploring the mechanisms of drug action or the development of novel chemical entities.
Used as a Chemical Reagent in Organic Synthesis:
1(2H)-Naphthalenone, 7-[(3-chlorophenyl)methoxy]-3,4-dihydroserves as a chemical reagent in organic synthesis, where its unique structure can be employed to synthesize a variety of complex organic molecules. This application takes advantage of the compound's reactivity and its potential to form new bonds or functional groups, contributing to the advancement of organic chemistry and the synthesis of novel compounds.

Upstream product

• 22009-38-7 7-hydroxy-1-tetralone 
• 766-80-3 1-bromomethyl-3-chlorobenzene 
• 6836-19-7 7-Methoxy-1-tetralone 

Downstream Products

• 163465-44-9 7-(3-Chlorobenzyloxy)-1-(4-methyl-1-piperazinyl)-naphthalene 

Relevant academic research and scientific papers

The Synthesis and Evaluation of C7-Substituted α-Tetralone Derivatives as Inhibitors of Monoamine Oxidase

Based on a previous report that α-tetralone (3,4-dihydro-2H-naphthalen-1-one) is a promising scaffold for the design of highly potent inhibitors of the enzyme, monoamine oxidase, the present study investigates the monoamine oxidase inhibitory properties of a synthetic series of fifteen C7-substituted α-tetralone derivatives. Arylalkyloxy substitution on C7 of the α-tetralone moiety yielded compounds with high inhibition potencies toward the human monoamine oxidase-B isoform with all compounds possessing IC50 values in the submicromolar range (0.00089-0.047 μm). The C7-substituted α-tetralones also were highly potent monoamine oxidase-A inhibitors with thirteen (of fifteen) compounds possessing IC50 values in the submicromolar range (0.010-0.741 μm). The α-tetralones were, however, in each instance selective for monoamine oxidase-B over the monoamine oxidase-A isoform. Dialyses of enzyme-inhibitor mixtures show that, while a representative inhibitor acts as a reversible monoamine oxidase-A inhibitor, inhibition of monoamine oxidase-B is not readily reversed by dialysis. Using a molecular modeling approach, possible binding orientations and interactions of selected α-tetralones with the active sites of the monoamine oxidases are also proposed. This study suggests that C7-substituted α-tetralones are promising monoamine oxidase inhibitors and may represent lead compounds for the development of therapies for Parkinson's disease and depression. C7-Substituted α-tetralones act as high potency reversible inhibitors of human MAO-A and MAO-B. This class of compounds represent promising leads for the development of therapies for Parkinson's disease and depression.

Pyrazinyl-substituted naphthalene derivatives

Compounds of the formula where R1 is of the formulae R2 is —R4, —O—R4, —O—S (O)2—R4, —NR4R5, R4—(CH2)b—NH(C═X)—(CH2)—, R4—(CH2)b—O(C═O)NH—(CH2)c—(C═O)NH—, R4(C═O)NH—(C═O)NH—, —(CH2)b—NH(C═X)—(CH2)c—R4, R4—(CH2)b—O(C═)—(CH2)c—, —(CH2)b—O(C═O)—(CH2)c—R4, —NH(C═X)NH—R4, R4—O(C═O)O—, —O(C═)NH—R4, R4—O(C═O)NH—, —(CH2)b—(C═0)—(CH2)c—R4, —NH—S(O)2—R4, —C(OH)R4R5, —CH(OH)—R4, —(C═O)—NR4R5, —CN, —NO2, substituted C1 to C6 alkyl, substituted or unsubstituted C1 to C6 alkenyl, or substituted or unsubstituted C1 to C6 alkynyl, said substituted moieties substituted with a moiety of the formulae —R4, —R4R5, —O—R4, or —S(O)d—R4. These compounds are useful psychotherapeutics and are potent serotonin (5-HT1) agonists and antagonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotranmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.